Key Points – Lifecore reaffirmed its 2026 guidance for revenue of $120 million to $125 million and adjusted EBITDA of $20.5 million to $25 million, despite second-quarter revenue falling 6.2% year over year to $34.2 million and the net loss widening to $6.2 million. -…
ntractually committed fill-finish demand from the company’s largest customer is expected to double beginning in 2027 and exceed 2026 levels by more than 200% in 2028. Lifecore also completed a Japanese regulatory inspection without material issues, potentially expanding market access. – Lifecore added six development programs during the quarter and now has 11 programs that could commercialize by the end of 2028
Management expects stronger second-half results, supported by higher aseptic and development revenue, while targeting roughly $7 million to $10 million in full-year free cash flow. Lifecore Biomedical (NASDAQ:LFCR) reaffirmed its 2026 revenue and adjusted EBITDA guidance while outlining plans to support sharply higher fill-finish demand from its largest customer beginning in 2027. For the second quarter ended June 30, 2026, the contract development and manufacturing organization reported revenue of $34.2 million, down 6.2% from $36.4 million in the comparable prior-year quarter ended May 25, 2025.
The company changed its fiscal year-end to align with the calendar year, affecting the comparison periods it used for the quarter and first half. President and Chief Executive Officer Paul Josephs said the company remains focused on three growth priorities: expanding its existing commercial business, moving development programs toward commercialization, and adding programs through business development. Largest Customer Demand Expected to Rise Josephs said Lifecore’s contractually committed fill-finish demand from its largest customer is expected to double beginning in 2027.